Alnylam Pharmaceuticals, Inc. (ALNY) is expected to report earnings on Thursday, October 29, 2026, after the close. Estimated release time 08:05 ET. Consensus EPS estimate is $2.19.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $1.63 | $1.21 | -25.8% | $1.29B |
| 2026-04-30 | FY2026 Q1 | $0.87 | $1.51 | +73.2% | $1.17B |
| 2026-02-12 | FY2025 Q4 | $1.16 | $0.82 | -29.3% | $1.10B |
| 2025-07-31 | FY2025 Q2 | $-0.54 | $-0.51 | +6.2% | $773.69M |
| 2025-05-01 | FY2025 Q1 | $-0.89 | $-0.44 | +50.6% | $594.19M |
| 2025-02-13 | FY2024 Q4 | $-0.62 | $-0.65 | -4.8% | $593.17M |
| 2024-10-31 | FY2024 Q3 | $-0.92 | $-0.87 | +5.1% | $500.92M |
| 2024-08-01 | FY2024 Q2 | $-1.07 | $0.56 | +152.3% | $659.83M |
ALNY has beaten consensus EPS in 5 of its last 8 reported quarters.
See ALNY on the live calendar →